Klein S, Gastaldelli A, Yki-Järvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11–20. https://doi.org/10.1016/j.cmet.2021.12.012. Recent article on adipose tissue function in obesity.

CAS  Article  PubMed  Google Scholar 

Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377(9765):557–67. https://doi.org/10.1016/S0140-6736(10)62037-5.

Article  PubMed  PubMed Central  Google Scholar 

GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27. https://doi.org/10.1056/NEJMoa1614362.

Article  Google Scholar 

Gastaldelli A, Abdul Ghani M, DeFronzo RA. Adaptation of insulin clearance to metabolic demand is a key determinant of glucose tolerance. Diabetes. 2021;70(2):377–85. https://doi.org/10.2337/db19-1152.

CAS  Article  PubMed  Google Scholar 

Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978–89. https://doi.org/10.1172/JCI129186.

Article  PubMed  PubMed Central  Google Scholar 

van Vliet S, Koh HE, Patterson BW, Yoshino M, LaForest R, Gropler RJ, et al. Obesity is associated with increased basal and postprandial β-cell insulin secretion even in the absence of insulin resistance. Diabetes. 2020;69(10):2112–9. https://doi.org/10.2337/db20-0377.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–223. https://doi.org/10.1152/physrev.00063.2017.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Weir GC. Glucolipotoxicity, β-cells, and diabetes: the emperor has no clothes. Diabetes. 2020;69(3):273–8. https://doi.org/10.2337/db19-0138.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Prentki M, Peyot ML, Masiello P, Madiraju SRM. Nutrient-induced metabolic stress, adaptation, detoxification, and toxicity in the pancreatic β-cell. Diabetes. 2020;69(3):279–90. https://doi.org/10.2337/dbi19-0014.

CAS  Article  PubMed  Google Scholar 

Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014;20(1):103–18. https://doi.org/10.1016/j.cmet.2014.05.005.

CAS  Article  PubMed  Google Scholar 

Beals JW, Smith GI, Shankaran M, Fuchs A, Schweitzer GG, Yoshino J, et al. Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease. Hepatology. 2021;74(3):1287–99. https://doi.org/10.1002/hep.31822.

CAS  Article  PubMed  Google Scholar 

Liu T, Sun YC, Cheng P, Shao HG. Adipose tissue macrophage-derived exosomal miR-29a regulates obesity-associated insulin resistance. Biochem Biophys Res Commun. 2019;515(2):352–8. https://doi.org/10.1016/j.bbrc.2019.05.113.

CAS  Article  PubMed  Google Scholar 

Bays HE, Chapman RH, Grandy S, SHIELD Investigators’ Group. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61(5):737–47. https://doi.org/10.1111/j.1742-1241.2007.01336.x (Erratum in: Int J Clin Pract. 2007 Oct;61(10):1777-8).

CAS  Article  PubMed  Google Scholar 

Sarma S, Sockalingam S, Dash S. Obesity as a multisystem disease: trends in obesity rates and obesity-related complications. Diabetes Obes Metab. 2021;23(Suppl 1):3–16. https://doi.org/10.1111/dom.14290.

CAS  Article  PubMed  Google Scholar 

Khafagy R, Dash S. Obesity and cardiovascular disease: the emerging role of inflammation. Front Cardiovasc Med. 2021;25(8):768119. https://doi.org/10.3389/fcvm.2021.768119.

CAS  Article  Google Scholar 

Blaha MJ, Rivera JJ, Budoff MJ, Blankstein R, Agatston A, O’Leary DH, et al. Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(6):1430–8. https://doi.org/10.1161/ATVBAHA.111.223768.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Cohen RV, Pereira TV, Aboud CM, Petry TBZ, Lopes Correa JL, Schiavon CA, et al. Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial. JAMA Surg. 2020;155(8):e200420. https://doi.org/10.1001/jamasurg.2020.0420.

Article  PubMed  PubMed Central  Google Scholar 

Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54. https://doi.org/10.1056/NEJMoa1212914 (Erratum in: N Engl J Med. 2014 May 8;370(19):1866).

CAS  Article  Google Scholar 

Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913–21. https://doi.org/10.1016/S2213-8587(16)30162-0.

Article  Google Scholar 

Wang J, Shen X, He S, An Y, Gong Q, Li H, Zhang B, Shuai Y, Chen Y, Hu Y, Li G. Hypertriglyceridaemia predicts subsequent long-term risk of cardiovascular events in Chinese adults: 23-year follow-up of the Daqing Diabetes Study. Diabetes Metab Res Rev. 2019;35(6):e3163. https://doi.org/10.1002/dmrr.3163.

CAS  Article  PubMed  Google Scholar 

Strelitz J, Lawlor ER, Wu Y, Estlin A, Nandakumar G, Ahern AL, et al. Association between weight change and incidence of cardiovascular disease events and mortality among adults with type 2 diabetes: a systematic review of observational studies and behavioural intervention trials. Diabetologia. 2022;65(3):424–39. https://doi.org/10.1007/s00125-021-05605-1.

Article  PubMed  Google Scholar 

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85. https://doi.org/10.1016/S2213-8587(19)30249-9 (Erratum in: Lancet Diabetes Endocrinol. 2020 Mar;8(3):e2).

CAS  Article  PubMed  Google Scholar 

Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76. https://doi.org/10.1056/NEJMoa1200225.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Amouyal C, Andreelli F. Increasing GLP-1 circulating levels by bariatric surgery or by GLP-1 receptor agonists therapy: why are the clinical consequences so different? J Diabetes Res. 2016;2016:5908656. https://doi.org/10.1155/2016/5908656.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A. 1992;89(18):8641–5. https://doi.org/10.1073/pnas.89.18.8641.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351. https://doi.org/10.1016/j.molmet.2021.101351. (Interesting and current review on the clinical physiology of GLP-1 and GLP-1 RA to understand their use in the treatment of obesity)

CAS  Article  PubMed  Google Scholar 

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102. (Complete review for the clinician of the use of GLPI-RA)

CAS  Article  PubMed  Google Scholar 

Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003;114(2–3):115–21. https://doi.org/10.1016/s0167-0115(03)00111-3.

Article  PubMed  Google Scholar 

Nauck MA, Meier JJ. GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family. Diabetes. 2019;68(5):897–900. https://doi.org/10.2337/dbi19-0005.

CAS  Article  PubMed  Google Scholar 

Christensen MB, Gasbjerg LS, Heimbürger SM, Stensen S, Vilsbøll T, Knop FK. GIP’s involvement in the pathophysiology of type 2 diabetes. Peptides. 2020;125:170178. https://doi.org/10.1016/j.peptides.2019.170178.

CAS  Article  PubMed  Google Scholar 

Holst JJ, Andersen DB, Grunddal KV. Actions of glucagon-like peptide-1 receptor ligands in the gut. Br J Pharmacol. 2022;179(4):727–42. https://doi.org/10.1111/bph.15611.

CAS  Article  PubMed  Google Scholar 

Azmy Nabeh O, Ishak Attallah M, El-Sayed E-G. The pivotal relation between glucagon-like peptides, NFκB and inflammatory bowel disease. Clin Exp Pharmacol Physiol. 2020;47(10):1641–8. https://doi.org/10.1111/1440-1681.13361.

CAS  Article  PubMed  Google Scholar 

Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metab. 2021;23(Suppl 3):5–29. https://doi.org/10.1111/dom.14496. (Excellent review on the cardiovascular actions of GLP-1RA)

CAS  Article  PubMed  Google Scholar 

Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001;86(9):4382–9. https://doi.org/10.1210/jcem.86.9.7877.

CAS  Article  PubMed  Google Scholar 

Ast J, Arvaniti A, Fine NHF, Nasteska D, Ashford FB, Stamataki Z, et al. Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. Nat Commun. 2020;11(1):467. https://doi.org/10.1038/s41467-020-1430